Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein Sells 57,765 Shares

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 57,765 shares of Insmed stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $101.78, for a total value of $5,879,321.70. Following the completion of the transaction, the chief financial officer now owns 93,536 shares of the company's stock, valued at approximately $9,520,094.08. This trade represents a 38.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, June 10th, Sara Bonstein sold 57,766 shares of Insmed stock. The shares were sold at an average price of $89.12, for a total value of $5,148,105.92.
• On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The shares were sold at an average price of $71.50, for a total value of $112,898.50.
• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $601,474.70.

Insmed Trading Down 3.0%

Shares of Insmed stock traded down $3.11 during trading on Thursday, reaching $101.74. The company's stock had a trading volume of 3,949,206 shares, compared to its average volume of 2,180,047. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83. The firm's 50-day moving average is $77.47 and its two-hundred day moving average is $75.35. The company has a market cap of $19.30 billion, a price-to-earnings ratio of -17.10 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.06) earnings per share. On average, sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Hedge Funds Weigh In On Insmed

Large investors have recently bought and sold shares of the stock. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares during the period. Norges Bank bought a new stake in Insmed during the 4th quarter valued at $126,606,000. Adage Capital Partners GP L.L.C. boosted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period. Nuveen LLC bought a new stake in Insmed in the 1st quarter worth $88,351,000. Finally, Vanguard Group Inc. grew its holdings in Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after acquiring an additional 1,075,796 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Bank of America boosted their price target on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. The Goldman Sachs Group lifted their price objective on Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Citigroup upgraded Insmed to a "buy" rating in a research report on Tuesday, June 10th. Leerink Partners lifted their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Finally, HC Wainwright boosted their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $106.80.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.